Abstract 615P
Background
Vascular endothelial growth factor receptor (VEGFR) inhibitors have demonstrated promising activity for recurrent and unresectable osteosarcoma. However, the use of VEGFR inhibitor for pulmonary metastatic osteosarcoma to improve resectability and postoperative outcome remains unexplored.
Methods
We did a single-arm phase 2 trial investigating the efficacy of adding anti-angiogenics to chemo for resectable pulmonary metastases (PMs) of osteosarcoma. Pts received VEGFR inhibitor Apatinib plus gemcitabine-docetaxel for 3 cycles pre- and 4 cycles post-metastasectomy, followed by Apatinib monotherapy maintenance until disease progression or unacceptable toxicities. Our primary endpoint was 12-month progression-free rate (12m-PFR) with a historical control of <30%. The primary endpoint would be met if ≥17 out of 39 evaluable pts were considered non-progression, corresponding to a pre-specified 12m-PFR of 50%.
Results
We enrolled 43 pts from Mar 2019 to Nov 2022 in this study, with 23 (54%) having ≥4 PMs, 12 (28%) having ≥10 PMs, and 24 (56%) having bilateral PMs. Extra tiny PMs were commonly detected and resected during surgical exploration. 39/43 pts (91%) finished their surgical procedures as planned, while 1 pt encountered tumor progression before metastasectomy and 3 failed to undergo the 2nd-stage metastasectomy after the 1st stage. Two pts were excluded from efficacy analysis due to major protocol violations. Of the remaining 41 pts, tumor volume reduction was seen in 30 (73.2%) pts before surgery, and 18 of the first 39 evaluable pts were progression-free at 12m (primary endpoint met). In the safety analysis (43 pts), ≥grade 3 toxicities were noticed in 29(67%) pts. One of the 15 deaths was due to post-operative complications and the remaining (14/15) due to tumor progression. The most common grade 3–4 toxicies were thrombocytopenia (26%), proteinuria (16%), anemia (14%), granulocytopenia(12%), pain(9.3%), pneumothorax(9.3%). Of note, only 2 ≥grade 3 postoperative wound problems following VEGFR inhibitor were observed.
Conclusions
Our study demonstrated a potential activity of combining Apatinib plus chemotherapy with metastasectomy for treating pulmonary metastatic osteosarcoma.
Clinical trial identification
NCT03742193.
Editorial acknowledgement
We are wholeheartedly gratefull to all participants and their parents in this study.
Legal entity responsible for the study
Ruijin Hospital, Shanghai Jiaotong University.
Funding
Shanghai Municipal Health Commission (grant No. 202140124) National Science Foundation of China (grant No. 82141116) Natural Science Foundation of Shanghai (grant No. 20ZR1434000).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract